May 29, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Linvoseltamab data in AL amyloidosis could have ‘tremendous implications’
CHICAGO — The bispecific antibody linvoseltamab exhibited rapid clinical activity among patients with relapsed or refractory systemic light chain amyloidosis, according to phase 1/phase 2 trial results presented at ASCO Annual Meeting.All 20 treated patients achieved objective response and 18 achieved hematologic complete response.
1,094 words~5 min read
